A Clinical Trial to Evaluate Efficacy and Safety of Two Different Formulations of Topical Calcipotriol in Patients With Mild to Moderate Plaque Psoriasis

Inclusion Criteria:

• Male or female patients (Non-pregnant) of plaque psoriasis aged 18 to 65 years havingeither Fitzpatrick skin type I-III or IV-VI.<br/>
• Diagnosis of stable plaque psoriasis for 6 month by a dermatologist with lesions onarms, legs or trunk.
• Mild to moderate psoriasis on Physician's global assessment (PGA),
• Body Surface Area (BSA) involvement of 5-10% (both included) and PASI ≥ 5.
• Patients must be willing to provide written informed consent and willing to complywith study requirements

Exclusion Criteria:

• Predominantly palmo-plantar, flexural, scalp and nail location of psoriasis
• Guttate, erythrodermic, or pustular psoriasis as sole or predominant form ofpsoriasis.
• Patient with any uncontrolled systemic disease
• Patient with positive serology tests like HIV, HCV & HBsAg.
• Patient with presence of any skin disease that might interfere with the diagnosis orevaluation of the test medications.
• Patient with spontaneously improving or rapidly deteriorating plaque psoriasis.
• Use of systemic agents within four weeks prior to screening.
• Use of biologic agents within four weeks prior to study entry.
• Use of topical drugs that might alter the course of psoriasis or has receivedultraviolet B treatment within two weeks prior to study entry.
• Use of phototherapy with psoralen ultraviolet A treatment within four weeks prior tostudy entry.
• Known sensitivity to any of the study treatments and/or study treatment's components.
• Need for surgery or hospitalization during the study
• Pregnant or nursing Female patient or planning a pregnancy
• Concurrent involvement in any other clinical study within 30 days prior to enteringthe study